3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Advanced Solid Tumours
5
Ovarian Neoplasms
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Previously Treated Non Small Cell Lung Cancer
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
1
Muscle Invasive Bladder Cancer
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Advanced Solid Tumors
1
Interventions
Injections
25
Carboplatin
17
Docetaxel
14
pembrolizumab
12
Paclitaxel
11
Bevacizumab
9
durvalumab
8
Cisplatin
8
Nivolumab
6
Fluorouracil
6
trifluridine tipiracil drug combination
5
tislelizumab
5
linifanib
5
Pemetrexed
5
Oxaliplatin
5
Leucovorin
5
zimberelimab
4
toripalimab
4
talazoparib
4
olaparib
4
Itraconazole
4
Irinotecan
4
Gemcitabine
4
Capecitabine
4
tremelimumab
3
sotorasib
3
sintilimab
3
fludarabine
3
depatuxizumab
3
atezolizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Solid Tumors
×
adavosertib
×
Clear all
NCT05008913
2022-09-06
ADME
AstraZeneca
Phase 1
Terminated
2 enrolled